cagrilintide news New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Three new #obesity drugs—high-dose semaglutide,
Description
Forbes, J., Krishnamurthy, K
If you have struggled to achieve your weight loss goals through traditional methods and have a BMI over 35 or are facing obesity-related health risks, you may be eligible
A current diagnosis by a medical professional
PDS subgroups
Pernicious anaemia (PA) is deemed an auto-immune disorder, whereby the body attacks its own cells
